Manchester Financial’s Unity Biotechnology UBX Stock Holding History

Manchester Financial’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-156	Closed	-$9K	–	606
2021 Q1	$9K	Buy	+156	New	+$10.6K	﹤0.01%	455

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Manchester Financial's UBX Position: Q2 2021 in Review

Manchester Financial sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 156 shares — an estimated $9K sold.

Manchester Financial first reported a position in UBX in Q1 2021 and held it in 1 quarter. The position peaked at $9K in Q1 2021. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

Manchester Financial reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
Manchester Financial sold 156 Unity Biotechnology shares in Q2 2021, an estimated $9K.
Manchester Financial first reported a position in Unity Biotechnology in Q1 2021 and held it in 1 quarter.
Manchester Financial's Unity Biotechnology position peaked at $9K in Q1 2021.
98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.